How evidence is interpreted
Evidence Methodology
Oriqeva matches the strength of its wording to the strength and relevance of the available evidence. A plausible mechanism can explain why an ingredient was included, but it is not the same as demonstrating a meaningful health outcome in people.
Evidence hierarchy is useful, but relevance comes first
Systematic reviews and meta-analyses can provide a broad view of a research area, while randomized controlled trials can answer more specific intervention questions. Observational studies can identify associations, and mechanistic or laboratory research can help explain biological plausibility. Animal and preclinical findings can generate hypotheses. Traditional use can provide historical context. None of those categories should be treated as automatically decisive without checking whether the evidence matches the question.
A meta-analysis of unrelated doses or strains may be less relevant to a particular formula than a well-designed human trial using the same ingredient form and comparable dose. Conversely, a single small study should not outweigh a larger body of consistent evidence without a clear reason.
Systematic reviews and meta-analyses
We generally give substantial weight to well-conducted systematic reviews and meta-analyses when they address a relevant ingredient, population, outcome, and intervention. We also consider heterogeneity, study quality, publication bias, and whether pooled results combine meaningfully different products or protocols. A statistically significant pooled result does not automatically mean a commercial supplement delivers a clinically meaningful effect.
Human trials
Human randomized trials can provide direct evidence about an intervention, but interpretation still depends on sample size, comparator, duration, dose, adherence, endpoints, and population. Surrogate markers are not always equivalent to outcomes a consumer actually cares about. A trial on a proprietary finished product is more directly relevant to that product than a trial on a different ingredient blend, but conflicts of interest and replication still matter.
Ingredient evidence versus finished-product evidence
This distinction is central to Oriqeva. Research supporting an ingredient does not prove that every product containing that ingredient will produce the same result. The commercial formula may use a different dose, chemical form, extraction method, delivery system, combination, or serving schedule. If no clinical study of the finished product is identified, our page says that finished-product efficacy is not established even when one or more ingredients have supportive research.
Dose, form, and population relevance
Evidence is more useful when the studied dose and ingredient form resemble the marketed product. If the product does not disclose a dose, we cannot assume that a dose used in research applies. Likewise, evidence from a narrowly defined population may not generalize to everyone. Age, health status, baseline nutrient status, medication use, and disease severity can all affect relevance.
Mechanistic, animal, and traditional-use evidence
Mechanistic research can explain a biochemical pathway or plausible rationale, while animal studies can explore effects that may justify further human research. These forms of evidence are useful context but normally support weaker efficacy language for human consumers. Historical or traditional use can describe how a substance has been used; it does not substitute for modern evidence of effectiveness or safety.
Our evidence-strength language
- Strong: consistent, relevant evidence supports the narrow claim being made.
- Moderate: meaningful support exists, but important limitations or uncertainty remain.
- Mixed: credible studies point in different directions or results vary substantially by protocol.
- Limited: evidence is sparse, indirect, small, early-stage, or not closely matched to the marketed use.
- Not established: the reviewed sources do not establish the specific product or claim.
Regulatory and safety evidence
For safety, labeling, and regulatory questions, Oriqeva prioritizes authoritative agencies and direct regulatory records where available. Regulatory status and evidence of effectiveness are separate questions. The absence of a warning is not proof of effectiveness, and a legally marketed supplement should not be described as approved for treating a disease unless the relevant authority actually provides that approval.
When evidence changes
Research evolves. A new systematic review, regulatory notice, finished-product trial, or safety signal can change the editorial assessment. When the change is material, Oriqeva updates the relevant page and records the meaningful revision rather than merely changing a date.